Congress funds biotech factories to build U.S. manufacturing muscle
H.R. 7936 — Bioindustrial Scale-Up for Supply Chains and Energy Resiliency Act of 2026 · Filed by James Baird (R-IN) · 7 cosponsors · Introduced Mar 16, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Energy to establish at least two federally funded 'bioindustrial technology maturation facilities' by 2030 to help biotechnology companies scale up manufacturing of bio-based products and materials. These facilities will operate as open-access user facilities where companies can test, pilot, and demonstrate new biotech manufacturing processes before commercial deployment, with $225.5 million authorized over fiscal years 2026–2030. The bill emphasizes geographic diversity, workforce development, data-sharing, and coordination with other federal agencies and private industry to build a resilient domestic biomanufacturing supply chain.
Why we flagged it
This bill establishes federal bioindustrial technology maturation facilities to support scaling of biotechnology manufacturing. It is fundamentally an infrastructure and R&D authorization bill, not a tax provision, regulatory carve-out, or commemorative measure.
What the text implies
- The 'open access' requirement for covered facilities may create tension between public-sector IP (placed in public domain for federal employee work) and private-sector IP protections, potentially affecting commercialization incentives and cost-sharing participation.
- Requirement for 'geographically diverse locations' and 'regional workforce development' may result in facility siting driven by political considerations rather than optimal technical or supply-chain logic, increasing construction costs and operational inefficiency.
The full analysis lists 5 implications of this text.
Who stands to gain
biotechnology companies (especially mid-stage and scale-up firms); biomanufacturing equipment vendors; fermentation technology providers